SC upholds NPPA’s Rs 4.6 crore penalty on Sun Pharma

Sun Pharmaceutical Industries Ltd, the sixth-largest generic pharmaceutical manufacturer in the world, had questioned NPPA’s demand notice of 2005 for payment of Rs 4.6 crore “to recover the higher price charged in relation to Roscilox, a brand of a Cloxacillin-based drug formulation, than that fixed by the govt under Drugs (Price Control) Order (DPCO)”.